Tesamorelin 6MG + CJC-1295 3MG + Ipamorelin 3MG + TCI-6/3/3MG

Tesamorelin 6MG + CJC-1295 3MG + Ipamorelin 3MG + TCI-6/3/3MG

$186.00

Combining Tesamorelin with CJC-1295 and Ipamorelin leverages their synergistic ability to stimulate growth hormone-releasing hormone (GHRH). This blend may accelerate fat loss, improve sleep quality, boost energy levels, enhance cognitive function, and support long-term natural GH production. The combination aims to optimize growth hormone release while supporting cellular repair and regeneration.

166 in stock

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

The Tesamorelin, CJC-1295, and Ipamorelin (TCI) blend is a powerful combination of three peptides that work synergistically to stimulate growth hormone (GH) release and promote various physiological benefits. This unique formulation combines the distinct mechanisms of action of each peptide to potentially enhance overall efficacy and provide a comprehensive approach to GH stimulation and its associated benefits.

  1. Tesamorelin:

    Tesamorelin is a synthetic GHRH analogue that has shown significant efficacy in reducing visceral adipose tissue in HIV-infected patients with lipodystrophy. Studies have demonstrated its ability to improve lipid profiles, reduce liver fat, and potentially benefit cognitive function. Tesamorelin has also been investigated for its effects on growth hormone secretion and metabolic parameters in various patient populations.

  2. CJC-1295:

    CJC-1295 is a long-acting GHRH analogue that has been shown to increase growth hormone and IGF-1 levels in healthy adults. Research has indicated its potential benefits in improving body composition, enhancing fat oxidation, and promoting muscle growth. CJC-1295 has demonstrated a favorable safety profile and the ability to maintain elevated GH levels for extended periods.

  3. Ipamorelin:

    Ipamorelin is a selective growth hormone secretagogue that stimulates GH release without significantly affecting other hormones. Studies have shown its potential in promoting muscle growth, improving bone density, and enhancing fat loss. Ipamorelin has also demonstrated potential benefits in sleep quality and recovery from exercise-induced muscle damage.

The combination of Tesamorelin, CJC-1295, and Ipamorelin in a single blend leverages the unique properties of each peptide to potentially enhance overall efficacy. While specific research on this exact combination is limited, the synergistic effects of these peptides are thought to provide a more comprehensive approach to GH stimulation and its associated benefits. The blend may offer enhanced fat loss, improved muscle growth and recovery, better sleep quality, and potential cognitive improvements.

The TCI blend represents an innovative approach to peptide therapy by combining three potent GH-stimulating peptides. This combination may offer several advantages:

  1. Comprehensive GH stimulation through multiple pathways
  2. Potential for enhanced efficacy compared to individual peptides
  3. Balanced approach to GH release, potentially minimizing side effects
  4. Convenience of administration in a single blend

  1. Clinical trials specifically evaluating the efficacy and safety of the TCI blend.
  2. Long-term studies to assess the sustained effects and safety profile of the combination.
  3. Comparative studies between the TCI blend and individual peptides or other GH-stimulating therapies.
  4. Investigation into optimal dosing regimens and cycling protocols for the TCI blend.
  5. Exploration of potential applications in various medical conditions beyond current indications.

  1. Clemmons DR, et al. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS ONE, 12(6): e0179538. [Online].
    Available: https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0179538
  2. Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/16352683/
  3. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/9849822/
  4. Peptide Sciences. (2024). Tesamorelin, CJC1295, Ipamorelin 12mg (Blend). [Online].
    Available: https://www.peptidesciences.com/tesamorelin-cjc1295-ipamorelin-12mg-blend
  5. Focal Point Vitality. (2024). Top 5 benefits of Growth hormone – CJC, Ipamorellin, Tesamorelin. [Online].
    Available: https://livvnatural.com/top-5-benefits-of-growth-hormone-cjc-ipamorellin-tesamorelin/
The Tesamorelin, CJC-1295, and Ipamorelin (TCI) blend represents a promising approach to growth hormone stimulation and its associated benefits. As with all peptide therapies, it is important to use this blend under medical supervision, and its potential benefits and risks require ongoing evaluation through further scientific studies and clinical trials.